Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis

PharmacoEconomics

Volumn 12, Issue 3, 1997, Pages 374-383

  Genç, Mehmet ^a,c   Mårdh, Per Anders ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b UPPSALA UNIVERSITY   (Sweden)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; OFLOXACIN;

ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COST BENEFIT ANALYSIS; FEMALE; GONORRHEA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; NEISSERIA GONORRHOEAE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0030883217     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712030-00009     Document Type: Article

References (26)

1. Moran J, Levine W. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl.: S47-65
2. Magid D, Douglas J, Schwartz J. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124: 389-99
3. Weber JT, Johnson RE. New treatments for Chlamydia trachomatis genital infection. Clin Infect Dis 1995; 20 Suppl.: S66-71
4. Genç M. Ruusuvaara L, Märdh P-A. An economic evaluation of screening for Chlamydia trachomatis in adolescent males. JAMA 1993; 270: 2057-64
5. Haddix AC, Hillis SD, Kassler WJ. The cost-effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995; 22: 274-80
6. Genç M, Mårdh P-A. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann Intern Med 1996; 124: 1-7
7. Nettleman MD, Jones RB. Cost-effectiveness of screening women at moderate risk for genital infections caused by Chlamydia trachomatis. JAMA 1988; 260: 207-13
8. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995; 274: 545-9
9. Holmes KK. Screening and the detection of gonorrhea. West J Med 1975; 123: 367-71
10. Phillips RS, Safran C, Aronson MD, et al. Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal. Am J Med 1989; 86: 297-302
11. Pappius EM, Komaroff AL, Vosseler MG, et al. Gonorrhea case-finding among asymptomatic men seeking ambulatory care: a cost-effectiveness analysis. Sex Transm Dis 1984; 11: 123-30
12. Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industralized countries. Am J Obstet Gynecol 1980; 138: 880-92
13. Gutman L, Wilfert CM. Gonococcal diseases in infants and children. In: Holmes K, Mårdh P-A, Sparling P. et al., editors. Sexually transmitted diseases. New York: McGraw Hill, Inc., 1990: 803-10
14. Hook EW, Roody RR, Hansfield HH. Ceftriaxone therapy for incubating and early syphilis. J Infect Dis 1988; 158: 881-4
15. Nettleman M, Smith V, Moyer N. Penicillin resistant Neisseria gonorrhoeae in low prevalence areas: implications for cost-effective management. Sex Transm Dis 1990; 17: 175-80
16. Friedland L, Kulick M, Biro F, et al. Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis. Ann Emerg Med 1996; 27: 299-304
17. WHO Advisory Group on Sexually Transmitted Diseases Treatments. Recommendations of the management of sexually transmitted diseases. Report of a WHO advisory group meeting on sexually transmitted diseases treatments; 1993 Feb 18-19. Report no: WHO/GPA/STD/93.1. Geneva: World Health Organization, 1993
18. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWRCDC Surveill Summ 1993; 42 (RR-14): 56-60
19. Katz B, Zwickl B, Caine V, et al. Compliance with antibiotic treatment for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis 1992; 19: 351-4
20. Blonna R, Legos P, Burlack P. The effects of an STD educational intervention on follow-up appointment keeping and medication taking. Sex Transm Dis 1989; 16: 198-200
21. Katz B, Caine V, Battaiger B, et al. A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with Chlamydia trachomatis. Sex Transm Dis 1991; 18: 36-40
22. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance Ann Intern Med 1984; 100: 258-68
23. Para W, Drotman D, Siegel K, et al. Patient counselling and behavioral modification. In: Holmes K. Mårdh P-A, Sparling P, et al., editors. Sexually transmitted diseases. New York: McGraw Hill. Inc., 1990: 1057-68
24. Lode H, Borner K, Koeppe P. et al. Azithromycin: review of key chamical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996; 37 Suppl. C: 1-8
25. Brown S, Pedersen A, Holmes K. Comparison of erythromycin base and estolate in gonococcal urethritis. JAMA 1977; 238: 1371-3
26. Hillis SD, Joesoef R, Marchbanks PA, et al. Delayed care for pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168: 1503-9